AKT1 and melanoma: (145) demonstrated that exosomes carrying PDGFRβ interact with receptors on melanoma cells, leading to dose-dependent activation of the PI3K/AKT signaling pathway and bypassing BRAF inhibition in the MAPK pathway, ultimately resulting in reduced drug sensitivity in melanoma cells.